SUMMARY Moderate titres of antiviral activity were demonstrated in 48-58% of sera obtained from patients suffering from seropositive and seronegative rheumatoid arthritis (RA), psoriatic arthritis, Reiter's syndrome, ankylosing spondylitis, and juvenile rheumatoid arthritis. Sera from blood donors and from patients with various noninflammatory diseases were positive in 16% of cases. The activity was species-specific, mediated by the homologous cells, and destroyed by treatment with trypsin and exposure to pH 2. Antibodies against human IFN-a did not neutralise the activity. These characteristics are compatible with those of IFN--y or immune interferon. Neither the presence nor the titre of IFN was correlated with disease activity defined by concentration of C-reactive protein, C3 concentration, and erythrocyte sedimentation rate. IFN--y was present in 4 of 10 synovial fluids from patients with RA. The titre in one of these was higher than in the corresponding serum, indicating local production in the rheumatoid joint.
Stimulation of lymphocyte blastogenesis and proliferation may be accompanied by induction of interferon (IFN). Such stimuli include either nonspecific mitogens' or cellular immune reactions by specific antigens.2 The immune-specific nature of the response has been demonstrated. 4 Similarly, IFN production can be shown in mixed cultures of tumour cells and lymphocytes5 and tumour cells and macrophages. 6 The IFN produced by the stimulated lymphocytes differs in several respects from the classical virus-induced interferons, for instance in sensitivity to treatment at low pH, stability at 56°C, cross-species activity, and antigenic specificity. The 
Results
The presence of antiviral activity in sera from different groups of patients is shown in For all the rheumatic diseases the frequency observed was significantly higherthan that in both the control groups (Fisher's exact test, p<005).
The antiviral activity was species-specific; no activity was obtained when tested in mouse L-929 cells. Further, the antiviral activity was trypsin-sensitive, and it did not neutralise directly the infectivity of vesicular stomatitis virus. Treatment of positive sera at pH 2 for 2 days eliminated the antiviral activity in 6 randomly selected sera containing high activity, suggesting that the interferon is most likely IFN-y. The antiviral activity in the same sera was not neutralised by the IFN-a antiserum. Unfortunately we did not have IFN--y antiserum at our disposal. Statistical testing of association by Fisher'sexacttest for all parameters showed no association with high or low interferon titres (p>010). Neither the presence of IFN nor the titres of the positive samples were positively or negatively correlated with disease activity in any patient groups as measured by ESR, complement factor C3, or CRP concentration ( Fig. 1 and Table 2 ). C3 usually behaves as an acute-phase reactant in these diseases14 but may be reduced in severe cases.
Interferon activity was tested in synovial fluid and in corresponding serum for 10 patients with RA in order to see whether there was a local production in the rheumatoid joint. Seven sera and 4 synovial fluids showed interferon activity over 16. They were all pH 2-sensitive. In one pair the titre in the synovial fluid, 28, was higher than that in the serum, 18 , suggesting local production in the joint. In the 3 other positive pairs the serum titres were higher than those in synovial fluid. Taken together with the synovial protein ratio to serum protein concentrations ( Table 3) this suggests that at least in one out of the 4 cases interferon was probably produced in the joint, while the others can be explained by passive influx into the joint of systemically produced interferons.
No relation was found between the IFN--y titres and treatment with glucocorticosteroids, either alone or in combination with azathioprine or penicillamine. Among the 15 patients who were on such treatment 9 (60%) had an IFN-y titre of >16. Neither was there any relation to the other forms of treatment (data not shown).
Discussion
The present data confirm the earlier report7 that circulating antiviral activity can frequently be demonstrated in the serum of patients suffering from rheumatoid arthritis. We also found such activity in various other rheumatoid diseases not previously studied for this factor. In contrast, in control persons, represented by healthy blood donors and various noninflammatory joint diseases such as osteroarthritis, it was only rarely present. The various inflammatory rheumatoid diseases represented in our study were similar in this respect.
The antiviral activity was characterised by standard criteria, as species specificity-i.e., activity only on human cells. The activity was destroyed by trypsin treatment, and by incubation at 56°C for 2 hours. Extracellular VSV was not neutralised by sera containing antiviral activity. Furthermore it was sensitive to exposure to pH 2 and was not neutralised by antihuman IFN-a globulin. These data strongly suggest that the activity is due to IFN-y. However, the data are not conclusive, for other antiviral serum factors are not excluded. The presence of IFN-y is consistent with the original observation by Hooks et al.7 that IFN in rheumatoid arthritis and systemic lupus erythematosus is of the IFN-y type, but it does not support a later report from the same group that IFN-a is also present."5
There is a consensus that IFN--y are produced by cells involved in the immune system."1 The main producers are apparently different lymphocyte populations, probably in co-operation with accessory cells such as monocytes and macrophages,17 and possibly macrophages in co-operation with other nonimmune cells. 6 The bulk of the data suggest that the main producers are T lymphocytes, but B lymphocytes have also been incriminated."8 A wide variety of substances may induce production,"9 mitogens such as phytohaemagglutinin (PHA), concanavalin-A (con-A), pokeweed mitogen (PWM), streptolysin 0, and staphylococcal enterotoxin, as well as antigens in sensitised cells, including bacterial, viral, and mycoplasmal antigens. In addition IFN- 25 In one of our patients the interferon titres in the synovial fluid were higher than in the serum, even when the relative protein concentration is taken into consideration, indicating that the interferon may have been produced in the affected joint. More systematic studies are required to define the site of interferon production. We 
